Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Drew, Y Ledermann, J Hall, G Rea, D Glasspool, R Highley, M Jayson, Gordon C Sludden, J Murray, J Jamieson, D
Drew, Y
Ledermann, J
Hall, G
Rea, D
Glasspool, R
Highley, M
Jayson, Gordon C
Sludden, J
Murray, J
Jamieson, D
Citations
Altmetric:
Abstract
Rucaparib is an orally available potent selective small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP) 1 and 2. Rucaparib induces synthetic lethality in cancer cells defective in the homologous recombination repair pathway including BRCA-1/2. We investigated the efficacy and safety of single-agent rucaparib in germline (g) BRCA mutation carriers with advanced breast and ovarian cancers.
Description
Date
2016-03-29
Publisher
Collections
Keywords
Type
Article
Citation
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. 2016, 114 (7):723-30 Br J Cancer